Politics
The GLP-1 blind spot: Why the FDA’s new eye stroke warning matters
▲ Sign in to vote stories up
Coverage 1 source · 1 report
Chronological.
-
The GLP-1 blind spot: Why the FDA’s new eye stroke warning matters
It forces the medical community to treat these therapies with clinical gravity instead of casual enthusiasm.
Discussion 0 comments